# TNO155

Source: https://onco.cc/drugs/tno155/  
OnCo record `tno155` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TNO155 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.

## Summary

TNO155 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Novartis Pharmaceuticals, in non-small-cell lung cancer, small-cell lung cancer. Described in the registry record as a shp2 inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: TNO155
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a shp2 inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of TNO155: https://clinicaltrials.gov/search?intr=TNO155

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)
- trials: [Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other](https://onco.cc/trials/nct07468071/), [Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation](https://onco.cc/trials/nct04699188/)

---
JSON: https://onco.cc/api/v1/entities/tno155.json